What happened

Molbio Diagnostics (NSE: MOLBIO) is frozen at its 20% upper circuit. Groww shows the stock at ₹1,509.40, up ₹251.50 or 19.99% against Wednesday's close of ₹1,257.90. Business Standard reports 12.31 million shares had already traded by 12:24 PM, with roughly 370,000 shares still queued as unmatched buy orders across NSE and BSE. That queue is what a circuit actually is: buyers with nobody willing to sell to them.

That's 35% in two sessions, and 87% above the ₹807 IPO price the company listed at on 17 August 2026.

Why it moved

The trigger is the Q1 FY27 result, put out on 8 September. This isn't a small beat. It's a swing from red to black:

• Net profit ₹52.74 crore, against a loss of ₹23.94 crore in Q1 FY26
• Total income ₹411.48 crore vs ₹100.47 crore — about four times bigger
• EBITDA ₹103.68 crore, against minus ₹14.50 crore a year earlier

The number underneath all three is the one that matters: Truenat test-kit volumes of 62.4 lakh units, versus 7.90 lakh a year ago. Nearly eight times. One caveat the headline skips — ₹57 crore of export orders originally due in the March quarter slipped and got booked in Q1 instead, so part of this quarter is borrowed from the last one.

Razor and blades, in a village clinic

Here is the bit worth learning. Molbio doesn't really sell machines. Truenat is a portable, battery-powered PCR analyser — a lab test in a box, results in about an hour, built for clinics that have no laboratory. The company has placed 12,500+ of these devices across 90+ countries. Each one then eats disposable test chips, forever.

So the device is the razor and the kit is the blade. Kit volume can go up 8x without the installed base going up 8x, and almost all of that extra revenue drops through to profit because the machines are already out there. That is exactly what turned a ₹14.5 crore EBITDA loss into ₹103.7 crore of EBITDA.

The business

• Truenat platform — devices plus consumable test chips, 43 tests covering about 30 diseases. TB is the anchor product; HIV and COVID sit alongside it.
• Bigtec Labs, a subsidiary, does the R&D behind the platform.
• Roughly 80% of revenue comes from government contracts — public health programmes and donor-funded tenders, not hospitals writing cheques.

So today's catalyst is the whole company, not one slice of it. That cuts both ways.

Is it expensive?

At ₹1,509.40, Groww puts the market cap near ₹14,498 crore and the trailing P/E at about 88. Screener.in shows FY26 sales of ₹1,446 crore, net profit of ₹164 crore and ROCE of 18.5%. A P/E in the high-80s is pricing several years of kit-volume growth as already delivered.

For scale, compare Poly Medicure, the listed medical-device maker: Screener.in shows it at a P/E of 54.5 on a market cap of ₹17,454 crore, earning ₹321 crore in FY26. Molbio is worth roughly the same as Poly Medicure while earning about half as much — and carries a multiple around 60% higher. Not a verdict, just the arithmetic.

Who it touches

• Listed medtech — Poly Medicure and other India device makers get a read-across on what the market will pay for consumable-led models.
• Central lab chains like Dr Lal PathLabs and Metropolis — every test done at a clinic on a Truenat is a test that never travels to a central lab. Slow-burn, structural, not a one-day effect.
• Government health budgets — with ~80% of revenue tied to tenders, Molbio's quarters follow the procurement calendar, not patient demand.

The one risk that flips this

Lumpiness. Management said it plainly: the company has a “non-linear revenue profile” and should be judged “on a full-year basis”. Revenue fell 27% sequentially in the same period, and the ₹57 crore Gulf export deferral shows how one delayed shipment moves a whole quarter. On a P/E near 88, a single slipped tender doesn't dent the earnings much — it dents the multiple.

As of 3:00 PM IST, 10 September 2026. Sources: Business Standard, Groww, Medical Buyer, Screener.in, 5paisa. For discussion and education only — not investment advice. Verify before acting.